丹栀逍遥散加减治疗卒中后抑郁的疗效及作用机制

江利敏; 刘向哲

doi:10.13422/j.cnki.syfjx.20190329

您当前的位置：

首页 >

文章列表页 >

丹栀逍遥散加减治疗卒中后抑郁的疗效及作用机制

临床 | 更新时间：2021-02-09

- 丹栀逍遥散加减治疗卒中后抑郁的疗效及作用机制
- Effect and Mechanism of Modified Danzhi Xiaoyaosan in Treating Post-stroke Depression
- 中国实验方剂学杂志 2019年25卷第3期页码：108-113
- 作者机构：
  
  河南中医药大学　第一附属医院，郑州　 450000
- 作者简介：
  
  江利敏，硕士，副主任医师，从事脑血管病及神经心理方面的研究，E-mail: jlmay2004@126.com
  *刘向哲，博士，教授，主任医师，研究生导师，从事脑血管病防治研究，E-mail: liuxiangzhe@163.com
- 基金信息：
  
  国家中医药行业科研专项(201507001-12)
- DOI：10.13422/j.cnki.syfjx.20190329
  中图分类号： R22;R242;R2-031;R287
- 收稿日期：2018-08-13，
  
  网络出版日期：2018-11-16，
  
  纸质出版日期：2019-02-05
- 稿件说明：
移动端阅览
江利敏, 刘向哲. 丹栀逍遥散加减治疗卒中后抑郁的疗效及作用机制[J]. 中国实验方剂学杂志, 2019,25(3):108-113.

Li-min JIANG, Xiang-zhe LIU. Effect and Mechanism of Modified Danzhi Xiaoyaosan in Treating Post-stroke Depression[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(3): 108-113.
江利敏, 刘向哲. 丹栀逍遥散加减治疗卒中后抑郁的疗效及作用机制[J]. 中国实验方剂学杂志, 2019,25(3):108-113. DOI： 10.13422/j.cnki.syfjx.20190329.

Li-min JIANG, Xiang-zhe LIU. Effect and Mechanism of Modified Danzhi Xiaoyaosan in Treating Post-stroke Depression[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(3): 108-113. DOI： 10.13422/j.cnki.syfjx.20190329.

摘要

目的:

观察疏肝散郁法（丹栀逍遥散加减）治疗卒中后抑郁(PSD)患者的临床疗效，并对其作用机制进行探讨。

方法:

选择PSD患者148例，随机分为观察组与对照组各74例，对照组口服草酸艾司西酞普兰10 mg·d

-1

，观察组在对照组的基础上加用丹栀消遥散加减3 g／次，2次／日。4周为1个疗程。比较两组患者汉密尔顿抑郁量表(HAMD)评分，神经递质功率，5-羟色胺(5-HT)，去甲肾上腺素(NE)水平以及炎症因子水平的变化。

结果:

观察组临床疗效明显优于对照组(

=2.97，

0.05)，且总有效率明显高于对照组(87.84%，74.32%，

=4.40，

0.05)。两组患者HAMD评分均随治疗时间的推移而下降(

0.05)，观察组HAMD评分整体水平明显低于对照组(

0.05)。脑涨落图仪测定两组患者6种神经递质的功率均随治疗时间延长而升高(

0.05)，观察组6种神经递质功率升高幅度均明显大于对照组(

0.05)，观察组6种神经递质功率整体水平及升高幅度均明显高于对照组(

0.05)。两组患者5-HT和NE水平均随治疗时间延长而升高(

0.05)，观察组5-HT和NE整体水平及升高幅度明显高于对照组(

0.05)。两组患者肿瘤坏死因子-

(TNF-

)，白细胞介素-1

(IL-1

)，白细胞介素-6(IL-6)水平均随治疗时间延长而下降(

0.05)，观察组TNF-

，IL-1

，IL-6整体水平及下降幅度明显低于对照组(

0.05)。

结论:

在应用传统抗抑郁药物的同时，加用丹栀逍遥散加减治疗PSD，疗效更明显，其作用机制可能与其抑制炎症因子表达有关，需要进一步深入地研究。

Abstract

Objective:

To observe the clinical efficiency of the liver soothing method(modified Danzhi Xiaoyaosan) in the treatment of post-stroke depression(PSD)

and explore its mechanism.

Method:

A total of 148 patients with PSD were randomly divided into study group and control group

with 74 cases in each group. Control group received Escitalopram Oxalate

10 mg·d

-1

. Study group received Shugan granule 3 g

twice a day

in addition to the therapy of control group. One course of treatment of 4 weeks. Hamilton depression scale (HAMD) score

neurotransmitter power

5-hydroxytryptamine(5-HT)

noradrenalin(NE) levels and inflammatory factors were compared between the two groups.

Result:

The clinical efficacy of study group was significantly better than that of control group(

=2.97

0.05)

and the total effective rate in study group was significantly higher than that of control group (87.84%

74.32%

=4.40

0.05). HAMD scores in both groups decreased in the process of treatment (

0.05). HAMD score in study group was reduced more significantly than that in control group (

0.05). The overall levels of HAMD score in study group was significantly lower than that in control group (

0.05). The power and overall levels of 6 kinds of neurotransmitters in both group were increased in the process of treatment (

0.05). The power of 6 kinds of neurotransmitters in study group were increased more significantly than that in control group (

0.05). The levels of 5-HT and NE in both groups increased in the process of treatment (

0.05). The overall levels of 5-HT and NE in study group were significantly higher than those in control group (

0.05). Tumor necrosis factor-

(TNF-

)

interleukin-1 beta(IL-1

) and interleukin-6(IL-6) levels in both groups decreased in the process of treatment (

0.05). TNF-

IL-1

and IL-6 levels in study group were decreased more significantly than those in control group (

0.05).

Conclusion:

Modified Danzhi Xiaoyaosan combined with traditional antidepressants has a more significant curative effect in the treatment of PSD. The mechanism may be related to the inhibition of the expressions of inflammatory factors. Further studies shall be conducted.

关键词

Keywords

references

Robinson R G , Jorge R E. Post-stroke depression: a review [J]. Am J Psychiatry , 2016 , 173 ( 3 ): 221 - 231 .

沈晓明，韩宁，马云枝，等 . 舒郁颗粒对卒中后抑郁大鼠模型海马单胺类神经递质及炎症细胞因子的影响 [J]. 中国实验方剂学杂志， 2011 , 17 ( 19 ): 177 - 180 .

中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组．中国急性缺血性脑卒中诊治指南2014 [J]. 中华神经科杂志， 2015 , 48 ( 4 ): 246 - 257 .

中华医学会精神科学会．中国精神障碍分类与诊断标准第三版（精神障碍分类） [J]. 中华精神科杂志， 2001 , 34 ( 3 ): 184 - 188 .

国家中医药管理局 . 中医病证诊断疗效标准 [M]. 北京：中国医药科技出版社， 2012 ： 33, 39 .

中华人民共和国卫生部 . 中药新药临床研究指导原则 [M]. 北京：中国医药科技出版社， 2002 ： 187 .

中华中医药学会 . 中医内科常见病诊疗指南 [M]. 北京：中国中医药出版社， 2008 ： 231 - 250 .

Schöttke H , Giabbiconi C M. Post-stroke depression and post-stroke anxiety: prevalence and predictors [J]. Int Psychogeriatr , 2015 , 27 ( 11 ): 1805 - 1812 .

卢伟明．艾司西酞普兰与舍曲林治疗脑卒中后抑郁患者的疗效及对炎症因子、NSE、NPY的影响 [J]. 中华全科医学， 2017 , 15 ( 8 ): 1340 - 1341,1401 .

胡丹，盛蕾．加味柴胡疏肝颗粒辅助治疗缺血性脑卒中后抑郁的疗效观察 [J]. 中草药， 2016 , 47 ( 21 ): 3866 - 3870 .

谢正，张志娟，于俊丽，等．舒肝颗粒在选择性5-羟色胺再摄取抑制剂应用中的减毒增效作用观察及机理探究 [J]. 中华中医药学刊， 2018 , 36 ( 4 ): 852 - 855 .

侯玉涛，林亚明．舒肝颗粒组方抗抑郁机制研究进展 [J]. 实用中医药杂志， 2014 , 30 ( 11 ): 1071 - 1073 .

唐卫东，李培芬，屈珍．脑涨落图仪检测抑郁症患者脑内神经递质功率变化特点分析 [J]. 精神医学杂志， 2012 , 25 ( 1 ): 25 - 28 .

JI X W , WU C L , WANG X C , et al . Monoamine neurotransmitters and fibroblast growth factor-2 in the brains of rats with post-stroke depression [J]. Exp Ther Med , 2014 , 8 ( 1 ): 159 - 164 .

Kim J S . Post-stroke mood and emotional disturbances: pharmacological therapy based on mechanisms [J]. J Stroke , 2016 , 18 ( 3 ): 244 - 255 .

Hadidi N N , Huna Wagner R L , Lindquist R. Nonpharmacological treatments for post-stroke depression: an integrative review of the literature [J]. Res Gerontol Nurs , 2017 , 10 ( 4 ): 182 - 195 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

解郁通络法对脑卒中后抑郁患者神经递质水平的影响

柴胡疏肝汤加减治疗肝气郁结型卒中后抑郁疗效及对患者血清神经递质、神经功能恢复的影响

基于“异病同治”探讨三仁汤临床应用及作用机制研究进展

中药及其活性成分促进抗生素抗菌的作用和机制研究进展

基于线粒体质量控制体系探索纤维蛋白原过表达冠心病血瘀证大鼠模型的作用机制